Advancing precision drug through innovative chemistry and advanced molecular technologies.
Integrated CDMO services spanning discovery, process development, custom synthesis and commercial manufacturing.
Delivering reliable CDMO solutions for innovative therapeutics worldwide.
Comprehensive technology platforms and CDMO expertise enabling the development and manufacturing of advanced therapeutics.
Leveraging advanced synthesis technologies and analytical expertise to enable efficient, scalable, and sustainable development of complex molecules.
CHEMOS is committed to building a CDMO brand that is product-led and synthesis-driven, providing end-to-end CDMO technical services to pharmaceutical and biotech companies worldwide. We focus on high-barrier fields including drug delivery systems (LNP, GalNAc), bioconjugation chemistry (ADC linkers), radiopharmaceutical chemistry (DOTA, NOTA), targeted protein degradation (PROTACs, molecular glues), and functional molecular building blocks. Leveraging advanced synthesis technologies and analytical platforms, we deliver full lifecycle solutions spanning discovery, process development, custom synthesis, manufacturing, and analytical development. We are dedicated to enabling efficient, low-carbon, and scalable development of innovative therapeutics, accelerating the journey from research to commercialization.
Explore the latest news and insights from Chemos, including industry trends, event updates and customer case studies.
This article shares insights from multi-kg GMP campaigns for SM-102, an ionizable lipid used in Moderna’s mRNA-LNP platform. Batch scale-up often suffers from purity drops below 98%, broadened impurity profiles, and residual solvent exceedances due to poor heat/mass transfer, hot spots, and inconsistent pH/temperature control. The solution is a telescoped continuous flow process with micro/meso-fluidic reactors, in-line PAT (HPLC/FTIR), and continuous work-up/crystallization. Results show consistent impurity fingerprints, 30–40% higher yield, 99.5% purity, and <500 ppm residual solvents, establishing continuous flow as the only robust, ICH-compliant route for commercial SM-102 supply.
Read More4-Chlorophenylhydrazine hydrochloride is a key intermediate for heterocyclic synthesis in pharmaceuticals and agrochemicals. Traditional processes face unstable diazonium salts, reducing agent caking, poor crystallization, low yields, high waste, and toxicity risks. The optimized CDMO process achieves high yield and purity through precise temperature/pH control, liquid reducing agent, and optimized crystallization, while integrating low‑temperature control, inert atmosphere, tail‑gas recycling, GMP production, and multi‑ton supply. Outsourcing reduces development time and compliance burdens. The process follows green chemistry principles and suits kinase inhibitors, antifungals, dyes, and more.
Read More
Trifluoromethanesulfonic anhydride (Tf2O) is a highly efficient electrophilic activator in modern pharmaceutical synthesis, enabling precise introduction of fluorine atoms or trifluoromethyl groups into molecular scaffolds. This enhances metabolic stability, lipophilicity, and biological activity—key parameters in drug discovery. Its mechanism involves converting alcohols into reactive triflates, facilitating nucleophilic substitutions and cross-couplings. As a professional CDMO, we offer custom synthesis of Tf2O at ≥99% purity, scalable from gram to kilogram and beyond, with stringent quality control and fast delivery. Our services help pharmaceutical companies streamline fluorination steps, shorten synthetic routes, reduce costs, and accelerate the transition from lab to commercialization for novel fluorinated APIs.
Whether you're in early discovery or late-stage commercialization, CHEMOS delivers efficient, reliable, end-to-end CDMO solutions powered by advanced synthesis technologies.
